AU2015338946B2 - Potent gamma-secretase modulators - Google Patents

Potent gamma-secretase modulators Download PDF

Info

Publication number
AU2015338946B2
AU2015338946B2 AU2015338946A AU2015338946A AU2015338946B2 AU 2015338946 B2 AU2015338946 B2 AU 2015338946B2 AU 2015338946 A AU2015338946 A AU 2015338946A AU 2015338946 A AU2015338946 A AU 2015338946A AU 2015338946 B2 AU2015338946 B2 AU 2015338946B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015338946A
Other languages
English (en)
Other versions
AU2015338946A1 (en
Inventor
Ronald BUCKLE
Robert Jason Herr
Graham Johnson
Nicholas Mayhew
William C. Mobley
Kevin D. RYNEARSON
Rudolph E. Tanzi
Steven L. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
University of California San Diego UCSD
Original Assignee
General Hospital Corp
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, University of California Berkeley, University of California San Diego UCSD filed Critical General Hospital Corp
Publication of AU2015338946A1 publication Critical patent/AU2015338946A1/en
Application granted granted Critical
Publication of AU2015338946B2 publication Critical patent/AU2015338946B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015338946A 2014-10-31 2015-10-30 Potent gamma-secretase modulators Active AU2015338946B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073553P 2014-10-31 2014-10-31
US62/073,553 2014-10-31
PCT/US2015/058429 WO2016070107A1 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Publications (2)

Publication Number Publication Date
AU2015338946A1 AU2015338946A1 (en) 2017-06-15
AU2015338946B2 true AU2015338946B2 (en) 2020-06-11

Family

ID=55858421

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015338946A Active AU2015338946B2 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Country Status (8)

Country Link
US (2) US10472346B2 (enExample)
EP (1) EP3212633B1 (enExample)
JP (1) JP6672296B2 (enExample)
CN (1) CN107406423B (enExample)
AU (1) AU2015338946B2 (enExample)
CA (1) CA2966423C (enExample)
MX (1) MX381224B (enExample)
WO (1) WO2016070107A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212633B1 (en) 2014-10-31 2019-12-04 The General Hospital Corporation Potent gamma-secretase modulators
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020231977A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
EP4396177A1 (en) * 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165263A1 (en) * 2013-03-12 2014-10-09 The Regents Of The University Of California, A California Corporation Gamma-secretase modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
EP0968711B9 (en) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Dermatological patch sheet and process for producing base sheet therefor
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
JP4762250B2 (ja) 2004-12-09 2011-08-31 エフ．ホフマン−ラ ロシュ アーゲー フェニル−ピペラジンメタノン誘導体
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2004625B1 (en) 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
US8410142B2 (en) 2007-03-02 2013-04-02 Merck Sharp & Dohme Corp. Bipyridine carboxamide orexin receptor antagonists
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
EP2401276B1 (en) 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
NZ597505A (en) 2009-07-15 2013-05-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
WO2011120026A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Pyrazolyl-pyrimidines as kinase inhibitors
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP3212633B1 (en) 2014-10-31 2019-12-04 The General Hospital Corporation Potent gamma-secretase modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165263A1 (en) * 2013-03-12 2014-10-09 The Regents Of The University Of California, A California Corporation Gamma-secretase modulators

Also Published As

Publication number Publication date
EP3212633A1 (en) 2017-09-06
EP3212633A4 (en) 2018-07-25
WO2016070107A1 (en) 2016-05-06
CA2966423C (en) 2023-10-24
MX2017005715A (es) 2018-02-23
CA2966423A1 (en) 2016-05-06
MX381224B (es) 2025-03-12
BR112017009010A2 (pt) 2017-12-26
AU2015338946A1 (en) 2017-06-15
US10472346B2 (en) 2019-11-12
CN107406423A (zh) 2017-11-28
US11117884B2 (en) 2021-09-14
JP6672296B2 (ja) 2020-03-25
JP2017533237A (ja) 2017-11-09
US20200055840A1 (en) 2020-02-20
US20180093967A1 (en) 2018-04-05
CN107406423B (zh) 2020-06-16
EP3212633B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
AU2015338946B2 (en) Potent gamma-secretase modulators
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
JP6938561B2 (ja) 重水素化２，４−チアゾリジンジオン及び治療方法
KR101464060B1 (ko) 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
DE60315516T2 (de) Pyridazinon-derivate als cdk2-hemmer
CN110036005B (zh) 酰胺衍生物及其在药物中的应用
WO2015085238A1 (en) Inhibitors of lpxc
CN106132950B (zh) 氨基吡啶类化合物和使用方法
CN108349964A (zh) N-（吡啶-2-基）-4-（噻唑-5-基）嘧啶-2-胺类化合物作为治疗性化合物
WO2003074525A1 (fr) Compose heterocyclique azote
EP3209652B1 (en) Tricyclic atropisomer compounds
JP2019512503A (ja) ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物
EP3675858B1 (en) Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition
JP6100755B2 (ja) （２−ヘテロアリールアミノ）コハク酸誘導体
CA3181351A1 (en) Nampt modulators
CN102796121B (zh) 3-芳基-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类衍生物及其应用
KR101854117B1 (ko) 1,6-이치환된 인돌 화합물을 함유하는 약물 내성 및 부작용이 저감된 만성골수성백혈병 치료제
BR112017009010B1 (pt) MODULADORES POTENTES DE GAMA-SECRETASE, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA REDUZIR O NÍVEL DE UMA ALOFORMA DE PEPTÍDEO Aß EM UMA CÉLULA E PRÓ-FÁRMACO
EP3700522A1 (en) Oxadiazoles and thiadiazoles as tgf-beta inhibitors
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
TW202321206A (zh) 轉甲狀腺素蛋白穩定化合物
HK1235064A1 (en) Indole carboxamides compounds useful as kinase inhibitors
HK1235064B (en) Indole carboxamides compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)